GMAB - Wutah pendapatan taun lumaku genmab.com

Genmab A/S (GMAB) attracts leading scientists through a Scandinavian culture of freedom and comprehensive benefits packages. A broad antibody portfolio and alliances with pharmaceutical behemoths minimize risks. The humanitarian status of its developments, which precludes sanctions, guarantees stability. This chart of LTM sales volume changes compared to last year visualizes the actual business dynamics, while 19.60 indicates the current level of this metric.

Genmab A/S - Wutah dodolan YoY (TTM) GMAB (periode 11.02.2024 - 15.11.2026)

Genmab - rincian analitis lan metrik utama (GMAB)

- rega lan prakiraan konsensus rega:

Bagan kurs Genmab US|GMAB - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Nilai pasar Genmab US|GMAB - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Rega Buku Saham Genmab|GMAB - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku genmab.com|GMAB - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

GMAB - Bathi resik perusahaan|Penghasilan resik sing dikarepake Genmab A/S|GMAB - Pangali P/E|Pangali Forward P/E genmab.com|GMAB - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Genmab US|GMAB - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Genmab|GMAB - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku genmab.com|GMAB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Genmab A/S

- indikator pendapatan dodolan lan penghasilan bisnis:

GMAB - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Genmab Corp|GMAB - Rasio rega marang pendapatan|Multiplikator forward rega marang pendapatan Genmab A/S|GMAB - Wutah dodolan YoY (TTM)

Pambiji fundamental perusahaan:Genmab US GMAB

Stable royalty payments from Darzalex form the cash flow foundation for Genmab A/S (GMAB), offsetting the high costs of developing new antibodies. The 12-month revenue growth trajectory reflects business scaling dynamics through a rolling sales pace, allowing investors to objectively assess operating value and the risks of demand stagnation when analyzing this metric.

Karo sapa Genmab A/S saingan